Amicus Therapeutics (FOLD) signed a license agreement to commercialize of Dimerix's DMX-200, a kidney disease therapy candidate for all indications, including Focal Segmental Glomerulosclerosis, or FSGS, the companies said Wednesday.

In exchange for the US rights, Dimerix will receive a $30 million upfront payment, up to $560 million in milestone payments, and tiered royalties on US sales, according to the statement.

DMX-200 is under a phase 3 study for the treatment of FSGS, with full enrollment for the study expected by the end of the year, the companies said.

Dimerix will continue to fund and execute the phase 3 study, while Amicus will be in charge of the regulatory process and commercialization in the US. Amicus will have the exclusive rights to develop DMX-200 in other future indications in the US.

Dimerix retains rights in other territories, according to the statement.